Version	Revision Date:	SDS Number:	Date of last issue: 2016/01/21
1.33	2016/02/04	100000008866	Date of first issue: 2013/12/23

SECTION 1. IDENTIFICATION

Product name : SYLVANT
Substance name : SYLVANT 100mg, 400mg vial, lyophilized product
siltuximab
CNTO 328

Manufacturer or supplier's details

Company name of supplier : Janssen Pharmaceuticals, Inc.

Address : 1125 Trenton-Harbourton Rd
Titusville NJ 08560
US

Telephone : (609) 730-2000

E-mail address Responsible/issuing person : SDSJanssen@its.jnj.com

Emergency telephone number : CHEMTREC US: 0800-424-9300
CHEMTREC International: +1 703-527-3887

Recommended use of the chemical and restrictions on use

Recommended use : Finished Pharmaceutical Product
Large Molecule Pharmaceutical intended for medical use
Monoclonal antibody
This SDS is only intended for occupational use and not for consumer use (see patient packaging insert for consumer use). This SDS is written to provide environmental, health and safety information for personnel that will be handling this finished pharmaceutical product. For health and safety information during manufacturing of this product we refer to the appropriate SDS for each component.
This dosage form is exempt from the requirements of the OSHA Hazard Communication Standard (US OSHA Standard 29 CFR Part 1910.1200).

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Not a hazardous substance or mixture.

GHS label elements

Not a hazardous substance or mixture., Medicinal products in the finished state, intended for the final user, are not subject to GHS labeling.

Other hazards

This Finished Pharmaceutical Product is non-hazardous based on chemical classification rules. Avoid direct contact and significant aerosol/dust exposure which has the remote possibilities of eliciting an allergic respons. May cause sensitization of susceptible persons.
This material is not likely to be significantly absorbed via occupational routes of entry due to its

chemical structure and large molecular weight.
Accidental injection may cause effects similar to those seen in clinical use and mentioned in the patient packaging insert.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Chemical nature : Solid

Hazardous components

Chemical name	CAS-No.	Concentration (%)
Siltuximab	541502-14-1	>= 30 - < 50

SECTION 4. FIRST AID MEASURES

If inhaled : If breathed in, move person into fresh air.
Consult a physician.

In case of skin contact : Take off all contaminated clothing immediately.
Wash off with plenty of water.
If symptoms persist, call a physician.
Wash contaminated clothing before re-use.

In case of eye contact : Rinse immediately with plenty of water, also under the eyelids, for at least 5 minutes.
Remove contact lenses.
If eye irritation persists, consult a specialist.

If swallowed : If swallowed, rinse mouth with water (only if the person is conscious).
Call a physician immediately.

Most important symptoms and effects, both acute and delayed : Consult the patient packaging insert for more information about this Finished Pharmaceutical Product.

Notes to physician : Treat symptomatically.
Consult the patient packaging insert for more information about this Finished Pharmaceutical Product.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Specific hazards during firefighting : Risk of dust explosion in case of organic fine powder.

Further information : Avoid dust formation.

Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	:	In the event of an accidental release the emergency response team must respond based on a risk assessment and use personal protective equipment as appropriate. Avoid direct contact with broken glass, plastic and other sharps. Avoid dust formation. Avoid breathing dust. Evacuate personnel to safe areas. Avoid direct contact and significant aerosol exposure. Do not break, crush or spill this Finished Pharmaceutical Product.
Environmental precautions	:	Should not be released into the environment.
Methods and materials for containment and cleaning up	:	Small spills: Cover with absorbent soaked in 10% bleach solution. Allow 30 minutes contact time. Large spills: Allow the dust/aerosol to settle for 30 minutes or use appropriate respiratory protection. Cover the spilled material with absorbent towels/ pads. Wet absorbent pad with 10% bleach solution. Allow 30 minutes contact time. Large spills + Small spills: Keep in suitable, closed containers for disposal. Treat recovered material as described in the section "Disposal considerations". Clean up with a 10% bleach (5.25% sodium hypochlorite) solution, 1 part bleach, mixed with 9 parts water is recommended for cleaning of surfaces and equipment. Clean spill location and adjacent surfaces thoroughly with ethanol or water with detergent. Special consideration may need to be evaluated based on specific hazards.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion	:	Avoid dust formation.
Advice on safe handling	:	Do not break, crush or spill this Finished Pharmaceutical Product. Avoid formation of dust and aerosols. Keep away from heat and sources of ignition. Ensure all equipment is electrically grounded before beginning transfer operations. To avoid thermal decomposition, do not overheat. Avoid inhalation, ingestion and contact with skin and eyes. Use personal protective equipment as required.

Conditions for safe storage	:	To maintain product quality, do not store in heat or direct sunlight. Store in original container. Keep containers tightly closed in a dry, cool and well-ventilated place. Keep away from heat and sources of ignition. Keep locked up.
Recommended storage temperature	:	2 - 8 °C

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Siltuximab	541502-14-1		2	J&J OEL/PBOEL HHC
	Further information: J&J has a hazard banding notation: PBOEL HHC. This substance is classified by J&J as being PBOEL HHC 2. This means that the OEL is estimated to be from 20 to 100 µg/m3			

Engineering measures : All personal protective equipment should be based on a risk assessment. Consult a Environment Health Safety expert if necessary.

Personal protective equipment

Respiratory protection : Engineering controls should always be the primary method of controlling exposures.
If respiratory protective equipment is needed for certain activities, the type as well as the corresponding protection factor will depend upon the risk assessment and air concentrations, hazards, physical and warning properties of substances present.
No special precautions required.

Hand protection

Remarks : No special precautions required.

Eye protection : No special precautions required.

Skin and body protection : No special precautions required.

Protective measures : The type of protective equipment must be selected based on the Environmental Health and Safety risk assessment. Consult a Environmental Health and Safety expert if necessary.

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

Remove gloves and wash hands when work with material is completed. Do not reuse gloves.
In some cases, wearing two pairs of gloves may be appropriate.
Contaminated work clothing should not be allowed out of the workplace.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	lyophilised cake, Vial
pH	:	5.3

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	None reasonably foreseeable.
Chemical stability	:	Stable under recommended storage conditions.
Possibility of hazardous reactions	:	No data available
Conditions to avoid	:	To avoid thermal decomposition, do not overheat. Heat, flames and sparks. Exposure to light.
Incompatible materials	:	None known.
Hazardous decomposition products	:	None known.

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity

No data available

Skin corrosion/irritation

No data available

Serious eye damage/eye irritation

No data available

Respiratory or skin sensitisation

Components:

Siltuximab

Remarks: Large protein biotherapeutics in the dry or reconstituted (solution in buffer) forms are not expected to elicit skin corrosion/irritation, skin sensitization, or cause damage to/irritate the eyes.

Assessment: Single-dose acute toxicity studies were not performed. This product is a large protein biotherapeutic intended for injection. It

is not expected to be absorbed via the oral, dermal, or inhalation routes of exposure.

Germ cell mutagenicity

Components:

Siltuximab

Germ cell mutagenicity - Assessment : Routine genotoxicity studies are not applicable to biotherapeutics as large proteins cannot diffuse into cells and interact with DNA or chromosomal material.

Carcinogenicity

IARC

No component of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA

No component of this product present at levels greater than or equal to 0.1% is identified as a carcinogen or potential carcinogen by OSHA.

NTP

No component of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Components:

Siltuximab

Effects on fertility :

Species: Mouse
Sex: male and female
Dose: > 100mg/kg/week
Exposure time: 7 weeks
Application Route: Subcutaneous; injection made in the back or neck of animal

Remarks: No adverse effects on sexual function and fertility.

Reproductive toxicity - Assessment : As maternal systemic exposure from handling is expected to be negligible and placental transfer of monoclonal antibodies in humans is very low during the period of organogenesis (1st trimester), embryo/fetal harm from worker exposure is considered unlikely.

STOT - single exposure

Product:

Remarks: Even though this does not meet GHS classification, inhalation of aerosol/dust from an acute exposure or significant overexposure may cause autoantibody formation or allergies.

STOT - repeated exposure

No data available

Repeated dose toxicity

Components:

Siltuximab
Species: Monkey
Application Route: intravenous injection
Exposure time: 3 - 6 months
Dose: 9,2 or 46mg/kg/week
Target Organs: Reproductive organs, Liver, Blood
Remarks: No significant adverse effects were reported

Repeated dose toxicity - Assessment	:	Single-dose acute toxicity studies were not performed. This product is a large protein biotherapeutic intended for injection. It is not expected to be absorbed via the oral, dermal, or inhalation routes of exposure.

Aspiration toxicity

No data available

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Product:

Toxicity to fish	:	Remarks: No data available
Toxicity to daphnia and other aquatic invertebrates	:	Remarks: No data available
Toxicity to algae	:	Remarks: No data available

Persistence and degradability

Product:

Biodegradability	:	Remarks: No data available

Bioaccumulative potential

Product:

Bioaccumulation	:	Remarks: No data available

Mobility in soil

No data available

Other adverse effects

Product:

Ozone-Depletion Potential	:	Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I

Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological information : There is no data available for this product.
Should not be released into the environment.

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : In accordance with National, Federal, State and Local regulations.
Decontaminate all waste before disposal (steam sterilization, chemical disinfection and/or incineration).

SECTION 14. TRANSPORT INFORMATION

International transport regulations

ADR
Not dangerous goods

RID
Not dangerous goods

DOT
Not dangerous goods

IATA
Not dangerous goods

IMDG
Not dangerous goods

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know Act

SARA 302 : No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.
This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

Massachusetts Right To Know

alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1	50 - 70 %

Pennsylvania Right To Know

alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1	50 - 70 %
Siltuximab	541502-14-1	30 - 50 %

New Jersey Right To Know

alpha-D-Glucopyranoside, beta-D-fructofuranosyl	57-50-1	50 - 70 %
Siltuximab	541502-14-1	30 - 50 %
L-Histidine, monohydrochloride, monohydrate	5934-29-2	1 - 5 %

California Prop 65 This product does not contain any chemicals known to State of California to cause cancer, birth defects, or any other reproductive harm.

Other regulations : Restricted to professional users.

This product is not subject to TSCA and TSCA 12(b) Export notification because Food, Drugs and cosmetic products are exempt.
Biosafety Regulations and Guidelines:
World Health Organization, Laboratory biosafety manual. - 3rd ed., ISBN 92 4 154650 6 (LC/NLM classification: QY 25) WHO/CDS/CSR/LYO/2004.11.
OSHA Bloodborne Pathogen Standard 29 CFR 1910.1030 and the OSHA Standard Interpretation on Applicability of 1910.1030 to Establish Human Cell Lines;
U.S. Department of Health and Human Services Public Health

Services, Biosafety in Microbiological and Biomedical Laboratories (BMBL) - 5th ed., HHS Publication No. (CDC) 21-1112

SECTION 16. OTHER INFORMATION

Further information

NFPA:



HMIS III:



0 = not significant, 1 =Slight,
2 = Moderate, 3 = High
4 = Extreme, * = Chronic

Revision Date : 2016/02/04

Date and Number Formats

This document uses the following notation for printing dates and numbers:

Date:	Dec 31th, 2012	as	2012/12/31
Numbers:	123456,78	as	123,456.78

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN